A New Insight into the Surgical Treatment of Primary Macronodular Adrenal Hyperplasia

PurposeThis prospective study presents the results of a new approach in the treatment of primary macronodular adrenal hyperplasia (PMAH), with simultaneous total adrenalectomy of the larger adrenal gland and partial adrenalectomy of the contralateral adrenal gland (adrenal-sparing surgery).Materials...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Endocrine Society 2020-08, Vol.4 (8), p.bvaa083-bvaa083
Hauptverfasser: Yoshiaki Tanno, Fabio, Srougi, Victor, Almeida, Madson Q, Ide Yamauchi, Fernando, Morbeck Almeida Coelho, Fernando, Nishi, Mirian Yumie, Claudia Nogueira Zerbini, Maria, Silvia Correa Soares, Iracy, Adelaide Albergaria Pereira, Maria, Laiz Silva Charchar, Helaine, Meneses Ferreira Lacombe, Amanda, Balderrama Brondani, Vania, Srougi, Miguel, Carlos Nahas, Willian, Mendonca, Berenice B, Luis Chambô, José, Candida Barisson Villares Fragoso, Maria
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PurposeThis prospective study presents the results of a new approach in the treatment of primary macronodular adrenal hyperplasia (PMAH), with simultaneous total adrenalectomy of the larger adrenal gland and partial adrenalectomy of the contralateral adrenal gland (adrenal-sparing surgery).Materials and MethodsWe performed a prospective study including 17 patients with PMAH treated surgically with adrenal-sparing surgery in a tertiary referral hospital, with a median follow-up of 41 months. Clinical, hormonal, and genetic parameters were evaluated before surgery and during follow-up. All patients had at least 1 radiological examination before and after the procedure.ResultsAmong the 17 patients, all but 1 patient had complete hypercortisolism control, and 12 recovered normal adrenal function after surgery. Significant improvement in clinical parameters was observed: weight loss (P = .004); reduction of both systolic (P = .001) and diastolic (P = .001) blood pressure; and reduction in the number of antihypertensive drugs (P < .001). Intra-, peri-, and postoperative complications were not observed.ConclusionAdrenal-sparing surgery is a safe and feasible procedure to treat patients with PMAH, providing a substantial chance of hypercortisolism control without the disadvantages of lifetime corticosteroid replacement.
ISSN:2472-1972
2472-1972
DOI:10.1210/jendso/bvaa083